Effect of treatment with alendronate in osteogenesis imperfecta type I: A case report

Keio Journal of Medicine

Volumn 53, Issue 4, 2004, Pages 251-255

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b  

^a KEIO UNIVERSITY   (Japan)

^b Mitate Hospital   (Japan)

Author keywords

Alendronate; Bone mineral density (BMD); Bone turnover; Fracture; Osteogenesis imperfecta

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; OSTEOCALCIN; PAMIDRONIC ACID;

ACQUIRED OSTEOPETROSIS; ADULT; ANTICOAGULANT THERAPY; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTICLE; BACKACHE; BLOOD LEVEL; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE TURNOVER; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRACTURE; HUMAN; HYPOCALCEMIA; LUMBAR SPINE; OSTEOGENESIS IMPERFECTA; PREMENOPAUSE; THROMBOEMBOLISM; TREATMENT OUTCOME; URINE LEVEL;

ADULT; ALENDRONATE; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; OSTEOGENESIS IMPERFECTA;

EID: 12344251566     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.53.251     Document Type: Article

References (38)

1. Niyibizi C, Wang S, Mi Z, Robbins PD: Gene therapy approaches for osteogenesis imperfecta. Gene Ther 2004; 11: 408-416
2. Albright JA, Grunt JA: Studies of patients with osteogenesis imperfecta. Bone Joint Surg Am 1971; 53: 1415-1425
3. Baron R, Gertner JM, Lang R, Vignery A: Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983; 17: 204-207
4. Riley FC, Jowsey J, Brown DM: Osteogenesis imperfecta: morphologic and biochemical studies of connective tissue. Pediatr Res 1973; 7: 757-768
5. Rauch F, Travers R, Parfitt AM, Glorieux FH: Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000; 26: 581-589
6. Brenner RE, Vetter U, Bollen AM, Morike M, Eyre DR: Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 1994; 9: 993-997
7. Astrom E, Soderhall S: Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 356-364
8. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952
9. Glorieux FH: Bisphosphonate therapy for severe osteogenesis imperfecta. J Pediatr Endocrinol Metab 2000; 13: 989-992
10. Gonzalez E, Pavia C, Ros J, Villaronga M, Vails C, Escola J: Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14: 529-533
11. Lee YS, Low SL, Lim LA, Loke KY: Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001; 160: 641-644
12. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH: Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-1850
13. King JD, Bobechko WP: Osteogenesis imperfecta. An orthopaedic description and surgical review. J Bone Joint Surg Br 1971; 53: 72-89
14. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, et al: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541
15. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, et al: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082
16. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, et al: A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 1999; 10: 183-192
17. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, et al: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000; 85: 3109-3115
18. Fleisch H, Reszka A, Rodan G, Rogers M. Bisphosphonates: Mechanism of action. In: Bilezikian JP, Raisz LG, Rodan GA, eds, Principles of Bone Biology. 2nd Ed, CA, Academic Press 2002; 1361-1385
19. Sillence DO: Osteogenesis imperfecta nosology and genetics. Ann NY Acad Sci 1988; 543: 1-15
20. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y: Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998; 16: 139-150
21. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, et al: Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research: Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19: 331-317
22. Menon RK, Gill DS, Thomas M, Kernoff PB, Dandona P: Impaired carboxylation of osteocalcin in warfarin-treated patients. J Clin Endocrinol Metab 1987; 64: 59-61
23. Jamal SA, Browner WS, Bauer DC, Cummings SR: Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 28: 829-832
24. Philip WJ, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS: Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 1995; 88: 635-640
25. Plantalech L, Guillaumont M, Vergnaud P, Leclercq M, Delmas PD: Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. J Bone Miner Res 1991; 6: 1211-1216
26. Szulc P, Chapuy MC, Meunier PJ, Delmas PD: Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993; 91: 1769-1774
27. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD: Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997 Mar; 82: 719-724
28. Iwamoto J, Takeda T, Ichimura S: Increased bone resorption with decreased activity and increased recruitment of osteoblasts in osteogenesis imperfecta type I. J Bone Miner Metab 2002; 20: 174-179
29. Nagata I, Aoki Y, Tsuchimoto M, Horiuchi H, Kishimoto T, Kiyoki M: General Pharmacological effects of alendronate (AHBuBP): effects of urinary excretion, blood system and immune system. Pharmacometrics 1995; 49: 541-548 (in Japanese)
30. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR: Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 2000; 160: 77-85
31. Gangji V, Appelboom T: Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999; 18: 266-267
32. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994; 74: 2949-2955
33. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785-1791
34. Iwamoto J, Takeda T, Ichimura S: Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 2002; 20: 228-234
35. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, et al: Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998; 13: 1032-1038
36. Iwamoto J, Matsu K, Takeda T, Ichimura S, Uzawa M: Effects of treatment with etidronate and alfacalcidol for osteogenesis imperfecta type I: a case report. J Orthop Sci 2003; 8: 243-247
37. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH: Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88: 986-992
38. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S: Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349: 457-463